Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: August 18, 2026 Corporate Relationship Department, National Stock Exchange of India, Limited BSE Limited, Exchange Plaza, 5th Floor, 1st Floor, Rotunda Building Plot No. C/1, G Block, Bandra-Kurla Complex, P.J Towers Dalal Street, Fort, Bandra (E), Mumbai 400001 Mumbai 400051 Stock Code: BSE – 530549 / NSE – SHILPAMED Dear Sir/Ma’am, Sub: Response on the news item captioned “Shilpa Medicare recalls over 27k vials of chemotherapy drug in US” published in the online edition of The Economic Times on August 17, 2026 – Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ref: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/…] This is with reference to the news item captioned “Shilpa Medicare recalls over 27k vials of chemotherapy drug in US”, published in the online edition of The Economic Times (www.economictimes.indiatimes.com) on August 17, 2026, available at the web link referred to above. In this connection, we wish to inform you that on July 29, 2026, the Company initiated a voluntary recall, at the retail / hospital level, 27, 923 vials (9,489 50 mL vials and 18,434 10 mL vials) of Pemetrexed Injection 100 mg/10 mL and 500 mg/50 mL (Pemetri RTU™) in the United States of America. The recall covers 04 batches; 02 of each strength of the said product and has been undertaken on account of atypical discoloration of the drug product, described as green to dark green in appearance. This observation is not consistent with the approved specification for appearance, defined as “clear, colorless to pale yellow to green- yellowish solution”. The recall has been classified by the US FDA as a Class II (hospital level) recall. The recall has been initiated voluntarily by the Company, out of an abundance of caution, in consultation with and in accordance with the procedure prescribed by the US FDA. No adverse event has been reported to the Company in respect of the affected batches. The recall is confined to the said batches and does not affect any other product of the Company, its manufacturing arrangements, or the supply of its products to customers. The Company does not foresee any material impact of the said recall, or of the aforesaid news item, on the financial position, operations or other affairs of the Company. The present intimation is being submitted by way of response on the aforesaid news item, in the interest of transparency and to ensure that the shareholders and investors at large have correct information. This intimation is also being hosted on the website of the Company at www.vbshilpa.com We request you to kindly take the above on record. For SHILPA MEDICARE LIMITED Ritu Tiwary Company Secretary & Compliance Officer Membership No.: 19056